Hybrid oligomers, their preparation process and pharmaceutical compositions containing them
View Patent ↗The present invention relates to compositions and methods for producing therapeutic oligomeric compounds. In one aspect the invention relates to methods for administering the oligomeric compounds for the treatment and prevention of disease, for example, a fungal infection, bacterial infection, or cancer, in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, pharmacologically active agent or a combination thereof.
1. A method for the treatment of a bacterial or fungal infection in an individual comprising: administering to an individual a therapeutic composition comprising an effective amount of at least one oligomeric compound or pharmaceutically acceptable salt thereof, selected from the group consisting of:
combinations thereof, together with a pharmaceutically acceptable carrier or excipient.
2. The method of claim 1 , wherein the individual suffers from a fungal infection, bacterial infection, or a combination thereof, and wherein the therapeutic is effective in treating or ameliorating the infection.
3. The method of claim 1 , wherein the fungal infection comprises aspergillosis and candidosis.
4. The method of claim 1 , wherein the therapeutic composition is administered orally.
5. The method of claim 4 , wherein the therapeutic composition is in the form of a tablet or capsule.
6. The method of claim 1 , wherein the therapeutic composition is administered parenterally.
7. The method of claim 6 , wherein the therapeutic composition is in the form of a solution.
8. The method of claim 6 , wherein the therapeutic composition is administered intravenously.
9. The method of claim 1 , wherein the amount of the at least one oligomeric compound or pharmaceutically acceptable salt thereof comprises from 1% to 95% by weight of the therapeutic composition.